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Background: The ineffectiveness of artesunate and amodiaquine tablets in malaria treatment remains a health
burden to WHO and governments of malaria-endemic countries, including Ghana. The proliferation of illegitimate
anti-malarial drugs and its use by patients is of primary concern to international and local drug regulatory agencies
because such drugs are known to contribute to the development of the malaria-resistant parasites in humans. No
data exist on quality of these drugs in the fishing village communities in Ghana although the villagers are likely
users of such drugs. A pilot study on the quality of anti-malarial tablets in circulation during the major fishing
season at a malarious fishing village located along the coast of Tema in southern Ghana was determined.
Methods: Blisterpacks of anti-malarial tablets were randomly sampled. The International Pharmacopoeia and Global
Pharma Health Fund Minilab protocols were used to assess the quality of anti-malarial tablets per blisterpacks
allegedly manufactured by Guilin Pharmaceutical Co Ltd, China (GPCL) and Letap Pharmaceuticals Ltd, Ghana (LPL)
and sold in chemical sales outlets at Kpone-on–Sea. Ferric chloride and cobaltous thiocyanate tests confirmed the
presence of active ingredients in the tablets. A confirmatory test for the active ingredient was achieved with
artesunate (ICRS1409) and amodiaquine (ICRS0209) reference standards. A high performance liquid chromatography
analysis confirmed the amount of artesunate found in tablets.
Results: Based on the International Pharmacopoeia acceptable range of 96/98 to 102% for genuine artesunate per
tablet, 10% [relative standard deviation (RSD): 3.2%] of field-selected artesunate blisterpack per tablets manufactured
by GPCL, and 50% (RSD: 5.1%) of a similar package per tablet by LPL, passed the titrimetric test. However, 100%
(RSD: 2.2%) of amodiaquine blisterpack per tablet by GPCL were found to be within the International Pharmacopeia
acceptable range of 90 to 110% for genuine amodiaquine in tablet, whilst 17% of a similar package per tablet by
LPL failed spectrophotometric testing.
Conclusion: Inadequate amounts of artesunate and amodiaquine detected in the tablets suggest that both
pharmaceutical companies may not be following recommended drug formulation procedures, or the active
pharmaceutical ingredients might have been degraded by improper storage conditions. Thus, drugs being sold at
Kpone-on-Sea, Ghana may likely be classified as substandard drugs and not suitable for malaria treatment.
Keywords: Artesunate and amodiaquine tablets, Counterfeit/substandard/falsified, Ferric chloride test, Cobaltous
thiocyanate test, Titrimetric, Spectrophotometry, High performance liquid chromatography* Correspondence: aaffum1@hotmail.com
1Nuclear Chemistry and Environmental Research Centre, National Nuclear
Research Institute, Ghana Atomic Energy Commission, P.O. Box LG 80, Legon,
Accra, Ghana
Full list of author information is available at the end of the article
© 2013 Affum et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Affum et al. Malaria Journal 2013, 12:220 Page 2 of 11
http://www.malariajournal.com/content/12/1/220Background
Counterfeit or substandard anti-malarial drug prolifera-
tion on the Ghanaian market is a public health concern
to the individual, the community and government. Mal-
aria is endemic in sub-Saharan Africa, which includes
Ghana [1]. The World Health Organization (WHO) re-
ports that in 2010 malaria caused an estimated 655,000
deaths worldwide, with most of the cases occurring
among African children [2]. The report predicts that over
250 million new cases of malaria occur each year and
about half the world’s population is at risk of malaria.
This public health hazard has attracted attention from
WHO and country-specific drug and healthcare regula-
tory agencies that seek to reverse the trend of anti-
malarial drug counterfeiting. WHO defines counterfeit
drugs as: “one which is deliberately and fraudulently mis-
labelled with respect to identity and/or source.
Counterfeiting applies to both branded and generic
products; counterfeit products may include products
with the correct ingredients or with the wrong ingredi-
ents, without active ingredients, with insufficient active
ingredient or with fake packaging” [3,4]. Substandard
drugs are genuine but may not meet drug quality specifi-
cations claimed by the manufacturer and those set by
WHO. Further, substandard drugs occasionally contain
sub-therapeutic amounts of active pharmaceutical ingre-
dients (API) and/or may show suboptimal release of API
(dissolution). Thus, exposing parasites to sub-lethal con-
centrations of API(s). Nevertheless, the percent API in
genuine medicines may also be reduced if they are de-
graded by extremes of temperature and humidity.
The use of substandard anti-malarial drugs is known to
contribute to the increasing population of drug-resistant
Plasmodium falciparum, because inaccurate dose of the ac-
tive pharmaceutical ingredient (API) in the tablets are not
sufficient to effectively clear the parasite from the infected
individual’s body system. In Ghana, the use of chloroquine
for malaria treatment has been banned because chlo-
roquine is not effective in clearing P. falciparum in an
infected person. For this reason, most malaria-endemic
countries have adopted artemisinin-based combination
therapy [artesunate (AS)–amodiaquine, AS–mefloquine,
AS–sulphadoxine/pyrimethamine)] as first-line treatment
of P. falciparum infections [5].
The global anti-malarial drug policy for Ghana re-
quires that uncomplicated P. falciparum malaria in-
fections are treated with a combined therapy of
artesunate-amodiaquine and artemether-lumefantrine
[6,7]. However, in cases of failed treatment in pregnancy
and severe malaria, a single dose quinine therapy has been
recommended. Further, for intermittent preventive treat-
ment a combined therapy of sulphadoxine-pyrimethamine
must be used. This has made artesunate-amodiaquine
tablets a target of the very sophisticated and highlyprofiteering substandard or counterfeit drug trade. The
extremely complex labelling by pharmaceutical companies
makes it more difficult for counterfeit anti-malarial tablets
to be visually identified [8]. In a survey on proliferation of
anti-malarial counterfeiting between 1999 and 2002, it was
found that 38 to 53% of artesunate anti-malarial tablets
produced by Indian and Chinese pharmaceutical compan-
ies were counterfeited [9]. Globally, it is estimated that
more than 10% of drugs that are traded are counterfeits
[10,11]. It is possible that most of these counterfeit anti-
malarial tablets are sent to underdeveloped and malaria-
endemic countries, including Ghana. Although no data
have been published on the level of anti-malarial coun-
terfeiting or substandard drugs by locally (Ghanaian)
based pharmaceutical companies, their contribution to the
counterfeit drug trade cannot be ignored. In a study to
compare quality of drug products approved by the Strin-
gent Regulatory Authority (SRA) and WHO, it was deter-
mined that African countries had a greater proportion of
SRA or WHO approved products (31.5%) than Indian
cities, but experienced higher failure rates (14.21%) than
Indian cities (7.83%). Further, products made in Africa
had the highest failure rate of 25.77%, followed by Chinese
products at 15.74%, Indian products at 3.70%, and
European/US products at 1.70%; and 17.65% for Chinese
products approved by the WHO [12]. The United Nations
Office on Drugs and Crime has implicated China and
India as major exporters of counterfeit drugs [13-15].
Therefore, monitoring of artesunate and amodiaquine,
combined or single therapy drugs, for substandard,
counterfeiting and degradation is necessary to alert and
prevent the spread of drug-resistant P. falciparum.
In Ghana, the extent of substandard or counterfeit anti-
malarial drugs has been evaluated in the major cities of
Accra and Kumasi, with a reported low failure rates in all
types of anti-malarials in 2010 to 54% of 2007 findings
[16-18]. However, the extent of counterfeit or substandard
drugs in fishing village settings in Ghana has not been
assessed because information and drug regulatory enforce-
ment is unavailable. For this reason Kpone-on-Sea (GPS
map shown in Figure 1), an isolated and the largest fishing
village community in Ghana, was selected as the study
site. Despite the recommended methods in the Inter-
national Pharmacopoeia monographs and Global Health
Fund Minilab Protocols, other analytical methods such as
colourimetric [19-21], liquid chromatography with ultra-
violet /evaporative light scattering (LC/UV/ELS), [22-25],
thin layer chromatography (TLC) [21,26-29], LC/mass
spectrometry –MS [9,23,30-32], vibrational spectroscopy:
FTIR/NIR, Raman and NMR [33-35] and electrochemical
[36] have been used to quantitate amodiaquine and
artesunate in anti-malarial tablets. However, such methods
need to be validated before they can be used for drug
quantitation or qualification in tablets.
Figure 1 GPS map of Kpone-On-Sea showing the locations of individual houses of the study area is a map of Ghana.
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quality of artesunate and amodiaquine tablets in circula-
tion during the major fishing season at Kpone-on-Sea, a
fishing village located along the coast in southern Ghana,
and to assess the extent of substandard, counterfeit, or de-
graded anti-malarial drugs in this unique geographical
location. This research is expected to encourage WHO,
health organizations and governments to be effective in
their drug monitoring programmes in poor communities




All chemicals were of analytical and American Chemical
Standard (ACS) grade. Hydroxylamine hydrochloride, so-
dium hydroxide, iron (III) chloride, phosphoric acid,
hydrochloric acid, phenolphthalein and bromophenol
blue, ethanol, methylene chloride, chloroform, acetone
and HPLC grade methanol, toluene, acetic acid, and aceto-
nitrile were purchased from Sigma Aldrich, St Louis, MO,
USA. Artesunate reference standard (ICRS1409) and
amodiaquine reference standards (ICRS0209) were pur-
chased from the European Directorate for Quality of Med-
icines and Healthcare (EMDQ), Strasbourg, France. Theanti-malarial drugs were purchased from all available
chemical stores at Kpone-on-Sea, Tema.
Instrumentation
UV-Vis Spectrophotometer was from Shimadzu, Japan.
Microcentrifuge was from France. The high performance
liquid chromatography (HPLC) system consisted of a
Waters 1525 Binary Pump, Waters 2487 Dual Wave-
length Absorbance Detector with an online Waters
degasser and inline filter. A Waters C-18 reversed phase
HPLC column of dimension 3.9 mm × 150 mm and 5
μm particle size was used for the separation. The manual
injection rheodyne valve has a volume of 20 μL. The
chromatograms were acquired, integrated and quantified
using Waters Breeze Software version 3.3. Class-A qual-
ity glassware was used in all laboratory work.
Study site
Kpone-on-Sea is one of the largest fishing village located
in the Tema Municipal Health Directorate, within the
Greater Accra Region of Ghana. It is located at 5°69’N,
0°06’E within the coastal savannah belt of West Africa
and has a population of about 15,000 people. It is bor-
dered on the east by Prampram, on the west by Tema,
south by the Gulf of Guinea (Atlantic Ocean), and north
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Zone. It is at an altitude 50-100 m above sea level and
has an equatorial climate. Temperatures range from 24.4
to 27.8°C with a mean of 26.1°C. Mean annual rainfall is
between 1,133 and 3,606 mm with an average relative
humidity index ranging from 78 to 85%. The land for-
mation and the drainage patterns of the four sectors of
the village are such that all water from the village drains
into a stream that lies on the outskirts of the village.
There is also a lagoon on the outskirts of the village
[17]. A recent study in the village showed a prevalence
of malaria (11%) with a peak parasite rate of 21% in chil-
dren aged one to five years. Plasmodium falciparum was
the major parasite detected in all positive blood slide ex-
aminations [18]. Most of the houses are constructed of
cement and corrugated iron roofing. The majority of the
residents (80%) are of the Ga and Ga-Adangbe ethnic
groups. Most of the inhabitants are fishermen and a
sizeable proportion is involved in vegetable farming
(Figure 1). The rationale for selecting this study site was
based on the level of education, population size, fishing
activities, and reported incident rate of malaria infec-
tions amongst the population.
Experimental design and sampling
Commercial artesunate-amodiaquine blisterpacks were
purchased randomly without alerting salepersons at
public chemical sales outlets of the research objective.
Random drug sampling design was done by following
Global Pharma Health Fund Minilab protocol, The
International Pharmacopoeia and WHO recommended
format for drug sampling [37]. The sampling unit for
this study was the anti-malarial tablets that are sold
from the various chemical outlets at Kpone-on Sea. A
total of 32 blisterpacks containing both AS+AM tablets
with the same lot or batch numbers manufactured by
Guilin Pharmaceutical Co Ltd, China (GPCL) and Letap
Pharmaceuticals Ltd, Ghana (LPL) were purchased be-
tween June and September in 2011 from 16 chemical
sales outlets (two blisterpacks/chemical sale outlet). The
lot or batch numbers were LQ110403A and 1370031 for
GPCL and LPL, respectively. Each blisterpack by GPCL
contained 12 each of artesunate and amodiaquine tablets
whilst those by LPL contain six each of artesunate and
amodiaquine tablets. The expiry date, manufacture date,
source of drug, batch (lot) number, dose amount and the
name of the chemical store sales outlet were recorded. All
samples were stored at room temperature until analysis.
Purchased blisterpacks manufactured by LPL were coded
as “L#” whilst those by GPCL as “G#” (where # equals
sample number). Each artesunate tablet manufactured by
GPCL has a dose of 150 mg and those by LPL a dose of
306 mg. Similarly, each amodiaquine tablet by GPCL has a
dose of 50 mg and those by LPL 100 mg. All drug sampleswere analysed before expiry date. Two blisterpacks of
same batch number were purchased from each chemical
sales outlet.
Sample treatment
A sample was defined as one dosage unit: such as a
blister or blisters in one package. Artesunate tablets
were separated from amodiaquine tablets from each
blisterpack and kept in a sealable rubber sachet. The
total artesunate tablets per blister (equivalent to full
treatment dose) were grounded in porcelain with a pes-
tle into fine powder. Similarly, the total amodiaquine
tablet per each blister was grounded into fine powder.
Powdered tablets were kept in dry, sealable, rubber sa-
chets at room temperature until analysed.
Qualitative test
A qualitative test based on physical and visual colour
formation was done by following WHO recommended
protocol for artesunate and amodiaquine.
Packages were visually screened and compared to
genuine samples when available to identify counterfeit
drugs. Anti-malarial packages with following defects
were classified as counterfeit: (1) apparent trademark
violations or other obvious labelling infractions; (2) ob-
vious poor packaging of product which suggested de-
graded product; (3) incorrect spelling of product name;
(4) manufacturing date after the expiry date of product;
(5) odd font or font size differed from innovator brands
or branded generic originals; and, (6) fake holograms.
Ferric chloride test for artesunate
This method was adapted from the methods in The Inter-
national Pharmacopoeia monograph for anti-malarials
[38]. Briefly, hydroxylamine hydrochloride solution was
prepared from 3.5 g of hydroxylamine hydrochloride, 95
mL of 535 g/L ethanol, 0.5 mL of 1g/L bromophenol and
sufficient 0.5 M potassium hydroxide/ethanol added until
a greenish tint developed. The final solution was diluted
to 100 mL with 535 g/L ethanol. Approximately 0.271 g
tab/50 mg artesunate (AR) by GPCL and 0.178 g tab/ 50
mg artesunate (AR) by LPL was weighed into individual
50 mL falcon tubes and 20 mL of 95% ethanol was added.
The mixture was shaken for 5 min, filtered and
centrifuged at × 300 g for another 5 min. Approximately
10 mL of filtrate was transferred into a clean test tube. Ap-
proximately 0.25 mL of hydroxylamine hydrochloride so-
lution was added, followed by 0.25 mL of 80 g/L sodium
hydroxide. The test samples, negative and positive con-
trols (prepared from ICRS1409) were boiled on a water
bath. The test tubes were allowed to cool to ambient
temperature after which two drops of 70 g/L hydrochloric
acid was added. Finally, two drops of ferric chloride was
added. A red-violet complex colour indicated a positive
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tive control.
Cobaltous thiocyanate test for amodiaquine
hydrochloride
This method was adapted from the protocol in the Inter-
national Pharmacopoeia monograph for anti-malarials
[39]. Briefly, cobaltous thiocyanate reagent was prepared
from 3.4 g cobalt chloride and 2.15 g of ammonium
thiocyanate with double-distilled water in 50 mL volu-
metric flask. About 0.273 g of artesunate powder corre-
sponding to each tablet dose was extracted with 0.1 M
hydrochloric acid and centrifuged. Approximately 2 mL
of supernatant was aliquoted into new tubes and a drop
of cobaltous thiocyanate reagent added to form a green
precipitate. The colour formed by amodiaquine refer-
ence standard (prepared from ICRS0209) and negative
control was used to identify positive and negative reac-
tions for the test samples.
Quantitative assay
The quantitative analysis of artesunate and amodiaquine
was achieved by using the individual methods in The
International Pharmacopeia monographs with little
modification. The methods included titrimetic, chroma-
tography and spectrophotometry [38,40].
Artesunate
A titrimetric method was used to determine artesunate
in tablets. Briefly, an artesunate powder equivalent to
0.25 mg artesunate API was weighed into 50 mL conical
flask and 25 mL of neutralized ethanol (prepared from
750 g/L ethanol, 0.5 mL phenolphthalein/ethanol and
sufficient carbonate-free 0.02 mol/L sodium hydroxide
to produce a faint pick colour) was added and titrated
against 0.05 mol/L sodium hydroxide with two drops of
0.01g/mL phenolphthalein indicator to a permanent
pick colour. Each mL of sodium hydroxide consumed
was equivalent to 19.22 mg anhydrous artesunate
(C19H28O8). Each sample was analysed in duplicate.
Positive control (prepared from ICRS1409) and negative
controls were titrated as the samples.
High performance liquid chromatography (HPLC)
Artesunate in the powdered anti-malarial tablets
manufactured by GPCL and LPL were determined by
following a validated WHO HPLC protocol specified in
the International Pharmacopoeia monograph [38].
Briefly, the HPLC analysis was done by using Waters
HPLC system set-up. A Waters HPLC C-18 column of
dimensions 0.39 mm × 150 mm id and 5 μm particle size
was equilibrated with a mobile phase prepared from
acetonitrile and phosphate buffer at pH 3 (44:56% v/v).
The absorbance wavelength for detection of artesunatewas set at 216 nm. Approximately 29.95 mg of pure
artesunate standard, 35.6 mg of (equivalent to 10 mg of
artesunate-active pharmaceutical ingredient) artesunate
tablet powder by LPL and 0.27.1 mg (equivalent to 20.1
mg of artesunate) of artesunate tablet powder by GPCL
were each dissolved in 10 mL of the mobile phase,
centrifuged and supernatant aliquoted into clean borosili-
cate glass vials. Approximately 20 μL of the artesunate
standard solution, filtered tablet solution were separately
analysed on the HPLC instrument using an isocratic elu-
tion flow rate of 1.0 mL/min over a 10-min run time. The
retention time of artesunate reference standard was used
to determine the retention time of artesunate in the pow-
dered tablets. The concentration of artesunate in each
powdered tablet was calculated from a calibration graph
of peak height versus concentration of artesunate refer-
ence standard. The reproducibility of the retention time
was determined.
Amodiaquine
A spectrophotometry method was used to determine
amodiaquine content in tablets. Briefly, approximately
100 μg/mL of stock amodiaquine reference standard
was prepared in 0.1 M hydrochloric acid from which a
working concentration of 30 μg/mL was prepared. Ap-
proximately 0.273g/105 mg of amodiaquine powder
manufactured by GPCL and 0.233g/153 mg powder by
LPL were each weighed into 100 mL volumetric flask
and diluted to 100 mL with 0.1 M hydrochloric acid.
Each sample solution was then 100-fold diluted to a
final concentration of 15 μg/mL. At a wavelength of
342 nm the optical density of the positive reference
amodiaquine standard (prepared from ICRS0209) and
samples was taken against a sample blank. The amount
of anhydrous amodiaquine C20H12ClN2O in each tablet
was calculated from the equation below:
Amodiaquine anhydrous mgð Þ
¼ 355:9=428:8ð Þ 20Cð Þ Au=Asð Þ
Where 355.9 = molecular weight of amodiaquine an-
hydrous; 428.8 = molecular weight of anhydrous
amodiaquine hydrochloride; C = concentration in μg/mL
calculated with reference to the anhydrous substance of
amodiaquine hydrochloride in the reference; Au = ab-
sorbance of the solution of the substance being exam-
ined; As = absorbance of reference solution.
Statistical analysis
Results were analysed by a one-sample t-test at confi-
dence level of 95% and test value of 0.05, using
Microsoft (Richmond, VA, USA) Statistical Package for
Social Sciences (SPSS) version 16.0.
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Qualitative analysis of anti-malarial tablets manufactured
by pharmaceutical companies
All the artesunate and amodiaquine tablets manufactured
by GPCL and LPL were found to contain some amount
of their respective API. The positive tests for the
amodiaquine and artesunate tablets were confirmed
with reference standards ICRS0209 and ICRS1409 re-
spectively. The negative control test (without the active
ingredients) did not form expected complex when com-
pared to the positive test.
Quantitative analysis of anti-malarial tablets
manufactured by pharmaceutical companies
Varying amount of artesunate-active ingredient in the
anti-malarial tablets manufactured by both pharmaceut-
ical companies were obtained but some APIs were
within the specification range of 96 to 102% for genuine
artesunate recommended by the International Phar-
macopoeia (Figure 2). Artesunate content in tablet/
blisterpack manufactured by GPCL varied between 90
and 101.1% of the amount of active ingredients specified
on the label. Similarly, artesunate content in tablets/
blisterpack manufactured by LPL varied between 93.9
and 106.7% of the label amount specified. An HPLC
analysis of the tablets however confirmed the amount of
artesunate in tablets obtained by the titrimetric method.
The percentage of amodiaquine-active ingredients in
anti-malarial tablets manufactured by both pharmaceut-
ical companies is shown in Figure 2. AmodiaquineFigure 2 Titrimetric analysis of artesunate API in tablets from GPCL a
standard; G1 to G10 = artesunate blisterpack by Guilin Pharmaceutical Co L
Ltd (n = 6); Total number of samples = 16.content in tablets/blisterpack manufactured by GPCL
varied between 99.4 and 105.4% of the amount specified
on label. A wide variation of between 5.1 and 106.0 % in
amount of amodiaquine-active ingredients was detected
in tablets/blisterpack manufactured by LPL. The accept-
able range for amodiaquine, recommended by the Inter-
national Pharmacopoeia, with regard to the method
used is between 90 and 110%. The results obtained from
the qualitative test for both anti-malarial drugs are sum-
marized in Table 1.
Discussion
Physical and visual examination of the manufacturers’
print on the insert leaflet, text on package hologram and
blisterpacks indicated that artesunate and amodiaquine
tablets were genuinely produced by GPCL and LPL. Fur-
ther, the positive confirmatory test from the qualitative
analysis of both tablets manufactured by the two phar-
maceutical companies confirmed their respective active
ingredient in the tablets. Thus, by the above visual in-
spection and qualitative test, one could be led to believe
that these anti-malarial tablets were genuine and had no
counterfeiting characteristics. However, further analysis
of the tablets found some with less active ingredient
(substandard). It is important to note that anecdotal evi-
dence from some markets supports the outcome of this
work [16]. It has been determined that counterfeiters in-
clude small amounts of the active ingredient in order to
pass basic qualitative test, which identifies the presence
of API only and not the amount. This deception wasnd LPL. Meaning of abbreviations: Artstd = artesunate reference
td (n = 10); L1 to L6 = artesunate blister pack by Letap Pharmaceutical
Table 1 Percentage of artesunate and amodiaquine anti-malarial tablet per blisterpack manufactured by GPCL and LPL














of 90 – 110%
HPLC Titrimetric Spectrophotometry
G1 66.4 92.8 Failed 102.3 Passed
G2 78.1 90.0 Failed 99.4 Passed
G3 85.3 92.2 Failed 104.9 Passed
G4 92.0 92.2 Failed 102.5 Passed
G5 108.9 101.1 Passed 101.5 Passed
G6 84.4 92.2 Failed 105.2 Passed
G7 109.2 92.8 Failed 105.4 Passed
G8 81.12 92.8 Failed 100.4 Passed
G9 99.3 92.2 Failed 100.5 Passed
G10 84.2 94.4 Failed 103.0 Passed
L1 102.1 106.7 Failed 103.1 Passed
L2 114.2 103.9 Failed 103.6 Passed
L3 97.1 100.0 Passed 106.0 Passed
L4 102.6 106.1 Failed 95.2 Passed
L5 93.7 96.7 Passed 5.1 Failed
L6 92.1 93.9 Failed 96.7 Passed
Artstd/Amdstd* 100 100.0 Passed 100* Passed*
Each anti-malarial blisterpack contains amodiaquine and artesunate tablets. Meaning of abbreviations: G1 to G10 refers to anti-malarial blisterpacks obtained from
GPCL, whilst L1 to L6 were obtained from LPL; Artstd refers to artesunate standard ICRS1409 obtained from EMDQ, Strasbourg, France); Amdstd* amodiaquine
standard ICRS0209 obtained from EMDQ, Strasbourg, France). PhInt refers to International Pharmacopoea. Note that HPLC was not done for amodiaquine because
it is not recommended in the International Pharmacopoea monograph.
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(Table 1). From Table 2, it can be seen that anti-malarial
drugs from GPCL have better precise formulation stan-
dards than those from LPL, even though both manu-
facturers were within the acceptable relative standard
deviation (RSD) of ± 2%. It can be seen that equal
amounts of excipients were added to the drugs
manufactured by GPCL. The weight of excipients added























Meaning of abbreviations: ()†= the first value represents coefficient of variation and
API means active pharmaceutical ingredient.contact with stomach fluids. Thus, API in tablets
manufactured by GPCL could be more efficiently released
to act on its target than API in tablets manufactured by
LPL. Bio-availability and bio-equivalence problems are
likely to be found in drugs formulated by LPL. Thus, tab-
lets by GCPL were found to have uniform weight as seen
in the lower RSD. Quantitative estimation of the API in
both anti-malarial tablets indicated variations in the
amount of the active ingredients present in each tablet pertured by Pharmaceutical companies
dose Number of tablet/
blisterpack
Weight of total tablet in blisterpack
per dose API (g/mg)
12 3.27 ± 0.03/600
(0.01, 0.8 %)†
6 2.13 ± 0.02/600
(0.2, 0.9 %)†




second value relative standard deviation.
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Using the International Pharmacopoeia specified range of
96/98 to 102% for genuine artesunate drugs, most of the
tablets were found to be substandard. About 17% of the
blisterpacks manufactured by GPCL passed the Inter-
national Pharmacopoeia specifications for artesunate while
83% failed, as shown in Figure 3. About 50% of artesunate
tablets manufactured by LPL failed. It is important to note
that substandard drug production is either unintentional
or negligent and requires regulatory measures to correct
[4]. The results obtained for artesunate by GPCL seem
to have improved the percentage of artesunate-active
pharmaceutical ingredient label claim which has been
reported [25,26], as shown in Additional file 1. In a re-
search work done in Accra, Ghana [26], only two (20%)
out of 10 single-dose artesunate (active ingredients in tab-
lets ranged between 69.3 and 92.8%), determined by the
HPLC, complied with The International Pharmacopoeia
standards for genuine artesunate tablets. Further, in
Kumasi, Ghana [25], the artesunate content of tablets pur-
chased from various pharmacies contained between 47.9
and 99.9% of API. The International Pharmacopoeia ac-
ceptable range for genuine amodiaquine tablet, with re-
gard to the method used in this study, is between 90 and
110%. Using this criterion, all amodiaquine tablets by
GCPL were found to be genuine whilst 17% of the tabletsFigure 3 Spectrophotometry analysis of amodiaquine API in tablets fro
reference standard; G1 to G10 = amodiaquine blister pack by Guilin Pharm
Pharmaceutical Ltd (n = 6); Total number of samples = 16.by LPL failed (Figures 2 and 3). The unexpectedly low
amount of amodiaquine and artesunate in the tablets,
judged by the standards set by The International Pharma-
copeia for genuine tablets, could be due to inadequate stor-
age conditions at high temperatures and humidity in the
chemical stores, or to insufficient amount of API added
during the formulation process by the manufacturers.
Harsh conditions can cause drug degradation, which can
lower the strength of active substance or increase degrad-
ation and toxicity. A comparison of percentage failure rate
in this study to data shown in Additional file 1 indicates
that percent counterfeit or substandard artesunate and
amodiaquine tablets are no different from previous values
obtained in sub-Saharan Africa and Southeast Asia. The
RSD obtained for artesunate packs manufactured by GPCL
and LPL were 5.2% and 5.1%, respectively.
The results obtained for HPLC analysis of artesunate
powder confirmed the amount of active pharmaceutical in-
gredient obtained from the titrimetric analysis was calcu-
lated from y = 2.0E+06x. R2 = 1.0. A retention time of 6
min was obtained for artesunate over a total run time of 10
min. The RSD between blisterpack of anti-malarial drugs
manufactured by GPCL and LPL was 2.1% and 5.1%, re-
spectively. The high RSD for tablets manufactured by LPL
could most likely be due to poor quality assurance and
quality control during the drug formulation process,m GPCL and LPL. Meaning of abbreviations: Amdstd = amodiaquine
aceutical Co Ltd (n = 10) L1 to L6 = amodiaquine blisterpack by Letap
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results obtained in this study. An UV/Vis spectrophoto-
metric method was not used to determine the amount of
artesunate but amodiaquine in the powdered tablet be-
cause artesunate has low molar extinction co-efficient and
its UV/Vis spectra or fluorescence property is not distinct.
The amount of amodiaquine-active ingredient detected
by the spectrophotometric method was not confirmed
by HPLC because of the complexities often associated
with the use of ion-pairs. Interestingly, the gold standard
method recommended by WHO for amodiaquine is the
spectrophotometric method.
The very low amodiaquine API found in amodiaquine
blisterpack could be caused by poor formulation prac-
tice, poor storage conditions and packing of tablets in
the blisterpack. Overall, these anti-malarial drugs with
subtherapeutic amounts of active ingredients could likely
lead to treatment failure, drug-resistant parasite, health
hazards, spread of anti-malarial-resistant P. falciparum,
and, finally death of the malaria-infected individuals.
Conclusion
Quantitative analysis of tablets manufactured by GPLC,
China and LPL, Ghana, which was reviewed under the
International Pharmacopoeia standards for anti-malarial
drugs, found variable amounts of artesunate-active ingre-
dients in their tablets. However, amodiaquine tablets from
both companies seem to indicate the expected amounts of
amodiaquine-active ingredients except one blisterpack by
LPL, which had exceptionally low amounts of the active
ingredient. The variable amount of artesunate-active in-
gredient in the tablets may be due to inadequate storage
conditions in chemical shops or less active ingredient
added during the drug formulation process, which can
confound drug quality assessment and detection of sub-
standard drug samples. Therefore, it is recommended that
the assessment on quality of artesunate and amodiaquine
tablets be tested at first point-of-entry of the drugs into
Ghanaian and other markets. Second, independent routine
testing of these drugs be done at the dispensers, hospitals
or pharmacies and results reconciled to first point-of-entry
before the drugs are passed to the patient. In order to
combat substandards, drug receiving points along the sup-
ply chain, such as customs border-points or at specific
geographic locations where a high estimated percentage of
drugs is passed, be equipped with the appropriate analyt-
ical tools to detect counterfeit or substandard drugs before
they are inventoried and distributed to consumers.
Although some organic impurities and degradants in
amodiaquine and artesunate tablets have been found dur-
ing other research work, future lines of research will look
for new impurities that might be harmful to patient. The
presence of unknown active ingredients was not detected
in both artesunate and amodiaquine tablets although suchphenomenon has been detected in some anti-malarial tab-
lets, but before the 1999 WHO data on anti-malarial
counterfeiting. Thus, this study confirms the predominant
existence of substandard artesunate and amodiaquine tab-
lets in circulation at Kpone-on-Sea in Tema. Finally, the
presence of substandard artesunate and amodiaquine tab-
lets at Kpone-on-Sea must alert health care and drug regu-
latory agencies to be vigilant and continually to monitor
these drugs to save preventable patient mortalities. In
order to prevent proliferation of poor quality artesunate
and amodiaquine tablets from jeopardizing the unprece-
dented progress and investment made in the control and
elimination of malaria infections, the police, scientists, the
pharmaceutical industry, governments and WHO must
work together to combat the problem. Pharmaceutical
companies must be alerted about these substandard
artesunate and amodiaquine so that better drug formula-
tion procedures will be followed, as well as improvement
made in the storage conditions for these drugs. Finally, the
recent spread of artemisinin resistance from East Asia to
African countries, present a new challenge and a danger
to human health which needs to be solved.
Additional file
Additional file 1: Report of poor quality artesunate and
amodiaquine tablets in Southeastern Asia and sub-Saharan Africa
1999 – 2011 [41-54].
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